Literature DB >> 11006244

Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

J H Sohn1, H J Kaplan, H J Suk, P S Bora, N S Bora.   

Abstract

PURPOSE: To explore the role of the complement system and complement regulatory proteins in an immune-privileged organ, the eye.
METHODS: Eyes of normal Lewis rats were analyzed for the expression of complement regulatory proteins, membrane cofactor protein (MCP), decay-acceleration factor (DAF), membrane inhibitor of reactive lysis (MIRL, CD59), and cell surface regulator of complement (Crry), using immunohistochemistry, Western blot analysis, and reverse transcription-polymerase chain reaction (RT-PCR). Zymosan, a known activator of the alternative pathway of complement system was injected into the anterior chamber of the eye of Lewis rats. Animals were also injected intracamerally with 5 microl (25 microg) of neutralizing monoclonal antibody (mAb) against rat Crry (5I2) or CD59 (6D1) in an attempt to develop antibody induced anterior uveitis; control animals received 5 microl of sterile phosphate-buffered saline (PBS), OX-18 (25 microg), G-16-510E3 (25 microg), or MOPC-21 (25 microg). The role of complement system in antibody-induced uveitis was explored by intraperitoneal injection of 35 U cobra venom factor (CVF), 24 hours before antibody injection. Immunohistochemical staining and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with Western blot analysis were used to detect the presence of membrane attack complex (MAC) and C3 activation products, respectively, in normal and antibody-injected rat eyes.
RESULTS: Complement activation product MAC was present in the normal rat eye, and intraocular injection of zymosan induced severe anterior uveitis. The complement regulatory proteins, MCP, DAF, CD59, and Crry, were identified in the normal rat eye. Soluble forms of Crry and CD59 were also detected in normal rat aqueous humor. Severe anterior uveitis developed in Lewis rats injected with a neutralizing mAb against Crry, with increased formation of C3 split products. Systemic complement depletion by CVF prevented the induction of anterior uveitis by anti-Crry mAb. Intracameral injection of anti-rat CD59 (6D1), anti-rat MHC class I antigen (OX-18), anti-rat Ig (G-16-510E3), or MOPC-21 caused no inflammatory reaction.
CONCLUSIONS: The results suggest that the complement system is continuously active at a low level in the normal eye and is tightly regulated by intraocular complement regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006244      PMCID: PMC1851917     

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  52 in total

Review 1.  Immunologic privilege of the eye.

Authors:  J W Streilein
Journal:  Springer Semin Immunopathol       Date:  1999

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Quantitative determinations of complement components and immunoglobulins in tears and aqueous humor.

Authors:  J W Chandler; R Leder; H E Kaufman; J R Caldwell
Journal:  Invest Ophthalmol       Date:  1974-02

4.  Complement levels in normal and inflamed aqueous humor.

Authors:  B J Mondino; H Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-03       Impact factor: 4.799

5.  Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement.

Authors:  E C Keystone; H U Schorlemmer; C Pope; A C Allison
Journal:  Arthritis Rheum       Date:  1977 Sep-Oct

6.  Alternate and classical pathway components of complement in the normal cornea.

Authors:  B J Mondino; H V Ratajczak; D B Goldberg; D J Schanzlin; S I Brown
Journal:  Arch Ophthalmol       Date:  1980-02

7.  Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.

Authors:  A E Davis; R A Harrison; P J Lachmann
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  Isolation and characterization of the third component of rat complement.

Authors:  M R Daha; M Stuffers-Heiman; A Kijlstra; L A van Es
Journal:  Immunology       Date:  1979-01       Impact factor: 7.397

9.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

10.  Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis.

Authors:  D Koffler; G Biesecker; B Noble; G A Andres; A Martinez-Hernandez
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  50 in total

Review 1.  Dynamic control of the complement system by modulated expression of regulatory proteins.

Authors:  Joshua M Thurman; Brandon Renner
Journal:  Lab Invest       Date:  2010-10-04       Impact factor: 5.662

2.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

3.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells.

Authors:  Jeong-Hyeon Sohn; Puran S Bora; Hye-Jung Suk; Hector Molina; Henry J Kaplan; Nalini S Bora
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

4.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

Review 5.  Age-related macular degeneration and the immune response: implications for therapy.

Authors:  Robert B Nussenblatt; Frederick Ferris
Journal:  Am J Ophthalmol       Date:  2007-08-15       Impact factor: 5.258

Review 6.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

7.  Oxidative stress and the regulation of complement activation in human glaucoma.

Authors:  Gülgün Tezel; Xiangjun Yang; Cheng Luo; Angela D Kain; David W Powell; Markus H Kuehn; Henry J Kaplan
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

Review 8.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

9.  Bisretinoid-mediated complement activation on retinal pigment epithelial cells is dependent on complement factor H haplotype.

Authors:  Roxana A Radu; Jane Hu; Zhichun Jiang; Dean Bok
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

10.  Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis.

Authors:  Fengqi An; Qing Li; Zhidan Tu; Hong Bu; Chi-Chao Chan; Rachel R Caspi; Feng Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.